Fibrocell Science (FCSC), an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints.
FCSC’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
FCSC has a collaboration agreement with Intrexon Corporation (XON)for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009; was incorporated in 1992 and is based in Exton, Pennsylvania.
March 10, 2018
Regenerative Medicine Earnings Scorecard - Q4 and FY17 - to date
March 6, 2018
RegMed Investors’ (RMi) closing bell; flickering
March 6, 2018
Fibrocell (FCSC) FDA Allowance of IND for FCX-013 for the treatment of Moderate to Severe Localized Scleroderma
March 4, 2018
RegMed Investors’ (RMi) wrapping-up January and February while determining March’s strength …
March 1, 2018
RegMed Investors’ (RMi) closing bell; the sector got spooked by the market sell-off
February 28, 2018
RegMed Investors’ (RMi) closing bell; sector traded up until the last hour
February 27, 2018
RegMed Investors’ (RMi) closing bell; sector trips to the downside
February 26, 2018
RegMed Investors’ (RMi) closing bell; the velocity of pricing movement
February 23, 2018
RegMed Investors’ (RMi) closing bell; sector reverses losses late afternoon
February 22, 2018
RegMed Investors’ (RMi) closing bell; the trading “tourists” stuck to the schedule
35 companies, 1 interpreter!
Insight, foresight and recommendation
Fibrocell Science (FCSC) has always been (to me) a disappointment. January '18 opened at $0.69, rolled barely up and slightly down to open 2/1 at $0.66 and sliding into second base at $0.67 on 2/16 ...Still early with a submission of an IND Application with the U.S. FDA for FCX-013, the Company’s gene therapy candidate for the treatment of moderate to severe localized scleroderma.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors